e-Edition
Obituaries
In Loving Memory
Magazines
Subscribe
Login to Comment
Register
jobs
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Life
Commentary
Contact
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
TriSalus Life Sciences, Inc. - Common Stock
(NQ:
TLSI
)
3.260
-0.190 (-5.51%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 22, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about TriSalus Life Sciences, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
May 20, 2026
From
Glancy Prongay Wolke & Rotter LLP
Via
Business Wire
TriSalus Life Sciences Inc. (TLSI) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
May 20, 2026
From
Law Offices of Howard G. Smith
Via
Business Wire
TLSI Investor Alert: Levi & Korsinsky Investigates TLSI (TLSI) for Potential Securities Fraud
May 19, 2026
From
Levi & Korsinsky, LLP
Via
Business Wire
TriSalus Life Sciences (NASDAQ:TLSI) Swings to Surprise Net Profit in Q1, But Revenue Miss Tempers Outlook
↗
May 12, 2026
Via
Chartmill
TriSalus Life Sciences Inc (NASDAQ:TLSI) Reports Q4 Revenue Beat and Narrowed Losses
↗
March 05, 2026
Via
Chartmill
Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
May 19, 2026
From
The Law Offices of Frank R. Cruz
Via
Business Wire
In today's session, these stocks are experiencing unusual volume.
↗
May 19, 2026
Via
Chartmill
There are notable gap-ups and gap-downs in today's session.
↗
May 19, 2026
Via
Chartmill
TriSalus (TLSI) Q1 2026 Earnings Transcript
↗
May 14, 2026
TriSalus (TLSI) Q1 2026 Earnings Transcript
Via
The Motley Fool
Wednesday's session: top gainers and losers
↗
May 13, 2026
Via
Chartmill
What's going on in today's session
↗
May 13, 2026
Via
Chartmill
There are notable gap-ups and gap-downs in today's session.
↗
May 13, 2026
Via
Chartmill
Stay updated with the stocks that are on the move in today's pre-market session.
↗
May 13, 2026
Via
Chartmill
TriSalus Life Sciences Q1 Earnings Call Highlights
↗
May 12, 2026
TriSalus Life Sciences (NASDAQ:TLSI) reported slightly lower first-quarter revenue and reduced its full-year 2026 revenue outlook, citing disruption from a broad commercial reorganization and a delayed...
Via
MarketBeat
Topics
Earnings
TriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth
May 12, 2026
From
TriSalus Life Sciences
Via
Business Wire
Real-World PEDD Study Published in the Journal of Comparative Effectiveness Research Shows Improved Clinical Outcomes and Meaningful Charge Avoidance
May 12, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors
May 04, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference Call
April 28, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting
April 09, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer
April 07, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models
March 18, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus (TLSI) Q4 2025 Earnings Call Transcript
↗
March 05, 2026
TriSalus (TLSI) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance
March 05, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences to Host Fourth Quarter 2025 Financial Results Conference Call
February 25, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering
February 20, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Proposes Public Offering
February 19, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors
February 09, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance
January 12, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025
December 04, 2025
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery™
November 18, 2025
From
TriSalus Life Sciences
Via
Business Wire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
wpDiscuz
Insert